Science Corner 61 | Expert Interview: Jennifer Greer - The Conversation Many Supplement Brands Skip
A conversation with Jennifer Greer, ND, scientific storytelling consultant and supplement industry veteran with over a decade of experience in naturopathic medicine, medical education, and evidence-based brand communication.
Many supplement brands have a science problem. Not a shortage of science, a shortage of honest storytelling about it.
I've been thinking about this for a while, and a recent conversation with Jennifer Greer, ND, crystallized it in a way I found hard to shake. Jenny spent years in naturopathic primary care before moving into supplement industry roles, including leading medical education at Thorne. She now works as a scientific storytelling consultant, helping brands understand how to communicate their evidence accurately, compliantly, and in a way that actually lands with real people. We covered a lot of ground.
Most consumers bring pharmaceutical expectations to supplement aisles, and that mismatch might explain more failed outcomes than the supplements themselves.
The Expectations Gap No One Talks About
Jenny's first observation hit close to home. She said most people come to supplements the way they come to medications: take it, feel something, fast. But many supplements don't work that way. They're operating at a nutritional and biochemical level that often takes weeks or months to produce measurable change, not hours.
This isn't a flaw. It's just different. But when consumers don't understand that, they quit too early. They decide the product "didn't work" after three weeks and move on. Jenny said the most important thing a practitioner can do is set that expectation upfront: here's what we're trying to do, here's the timeline, here's what subtle early progress might feel like before you notice a real difference.
I think brands could learn from that. Education about how a product works, and when to expect results, isn't just good science communication. It protects against the churn that happens when people quit a product which may take three months to have an impact.
"Scientifically Proven" Is Usually Neither
This one made me laugh, because I've seen it everywhere.
Jenny's biggest pet peeve in the industry, and she was not shy about it, is the phrase "scientifically proven." She made the distinction clearly: in science, proof requires many large-scale trials, repeated over time, producing consistent results. What most brands have is evidence. Promising evidence, sometimes. But not proof.
Using the word "proven" doesn't add authority. To anyone who understands science, it signals the opposite. And to the FDA, she noted, it's basically an invitation to come ask hard questions.
This matters because I think a lot of brands reach for that language to sound more credible, when what actually builds credibility is being precise about what the data shows and honest about where the gaps are. Consumers are smarter than we give them credit for, and trust, once eroded, is hard to rebuild.
Jenny's Anchor Evidence Framework
When I asked Jenny how she decides what science actually gets to anchor a brand's story, her framework was practical.
Start with your best human clinical trial evidence. Not the abstract, the actual trial. Was it powered adequately? Were the results what you think they are? She pointed out that reading abstracts can mislead even sharp people. From there, you build outward:
Human clinical trials first. This is your anchor. Evaluate the actual study, not just the abstract. Was it adequately powered? Do the results hold up when you read past the headline?
Mechanistic and preclinical research second. In vitro data and animal studies can support your story, but they shouldn't headline it. They fill in the biological picture, not the clinical one.
Traditional use where it applies. For herbs and botanicals with a long history of use, that history is part of the evidence she uses personally. And increasingly, clinical research is confirming what traditional medicine has argued for centuries.
She also made a point I want to highlight: if you don't have strong anchor evidence for a particular claim, the honest move is to find out what you do have evidence for, and build your story around that instead.
The Collaboration Most Brands Skip
This is the part I think gets companies into the most trouble.
Jenny's prescription for better supplement science communication is deceptively simple: loop in your science team from day one. Not after the formula is final. Not after the marketing copy is drafted. From the beginning, when product concepts are still being shaped.
Jenny's prescription for better supplement science communication is deceptively simple: Loop in your science team from day one
When science, marketing, R&D, and regulatory talk together early, you can design a product and its story simultaneously. You don't end up with marketing claims that have no evidence, or a formula that can't support what sales wants to say about it. The product has more longevity on the market because the story is true.
She put it plainly: cross-functional collaboration isn't just good process. It's what produces products people actually trust.
Science Literacy and Who We're Writing For
One data point in particular from Jenny has been sitting with me since we talked: fewer than one-third of US adults can readily understand the science section of the New York Times.
That's not a criticism of consumers. It's a reflection of how science education works in this country. But it does mean that making the science accessible isn't optional for supplement brands. It's the whole job.
Jenny draws a sharp distinction between communicating with practitioners versus general consumers. With practitioners, you can go deeper: clinical endpoints, study design, mechanism. With consumers, the story is about outcomes. What does this do for my life, and how does the evidence support that? Both audiences deserve accuracy. The depth just looks different.
She also made an important point about regulatory constraints: the FDA draws a real line between structure/function claims ("supports healthy immune function") and disease claims ("treats insomnia"). Brands that blur this line aren't just risking compliance issues. They're eroding the credibility of the whole category.
If this conversation got you thinking, the full video interview goes even deeper. Jenny gets into the clinical art behind formula development, how she evaluates products that come to her half-baked from an AI prompt, and the real-world messiness of getting science and marketing to actually collaborate.
She also shares the one supplement she won't travel without right now, and the everyday staple she thinks most people are dramatically underconsuming. Both answers surprised me. Watch the full interview to find out what they are.
--
Personal note from Jordan
I came into this conversation expecting to talk mostly about communication strategy. I left thinking more about trust.
What Jenny described, the gap between what supplement science actually shows and what brands claim it does, is something I bump into constantly in my own work here at SuppCo. The brands that build long-term credibility are the ones willing to say "the evidence is promising but not conclusive," or "this works for many people, but results vary." That kind of honesty feels risky. I think it's actually the safest thing you can do.
I'm also more convinced than ever that the timeline education piece is one of the most underserved parts of the consumer experience. We spend a lot of time talking about mechanisms and outcomes. We don't spend nearly enough time saying: give this three months before you evaluate.
If you're a brand reading this: your science team should be in the room before the formula is final. And your story should be as honest as your evidence. The consumers who find out you stretched the truth won't come back. The ones who trusted you because you were straight with them probably will.